Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Harrison, J. McGinnis, M. Crowther, Jeffrey Ginsberg, J. Hirsh (1998)
Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin.Archives of internal medicine, 158 18
P. Wells, M. Kovacs, J. Bormanis, M. Forgie, Donna Goudie, B. Morrow, J. Kovacs (1998)
Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection.Archives of internal medicine, 158 16
B. Hutten, M. Prins, M. Gent, Jeffrey Ginsberg, J. Tijssen, H. Büller (2000)
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 17
R. Hull, G. Raskob, G. Pineo, D. Green, A. Trowbridge, C. Elliott, R. Lerner, Jack Hall, Terence Sparling, H. Brettell, J. Norton, C. Carter, Ralph George, G. Merli, J. Ward, Warren Mayo, D. Rosenbloom, Rollin Brant (1992)
Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.The New England journal of medicine, 326 15
A. Choucair, P. Silver, V. Levin (1987)
Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism.Journal of neurosurgery, 66 3
S. Schulman, S. Granqvist, M. Holmström, A. Carlsson, P. Lindmarker, P. Nicol, S. Eklund, Sune Nordlander, G. Lärfars, B. Leijd, O. Linder, E. Loogna, H. Walter, S. Viering, M. Hjorth, J. Boberg (1997)
The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.The New England journal of medicine, 336 6
R. Schwarz, A. Marrero, K. Conlon, M. Burt (1996)
Inferior vena cava filters in cancer patients: indications and outcome.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 2
J. Heit, D. Mohr, M. Silverstein, T. Petterson, W. O'Fallon, L. Melton (2000)
Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.Archives of internal medicine, 160 6
S. Lopaciuk, H. Bielska-Fałda, W. Noszczyk, M. Bielawiec, W. Witkiewicz, S. Filipecki, J. Michalak, L. Ciesielski, Z. Mackiewicz, E. Częstochowska, K. Zawilska, A. Cencora (1999)
Low Molecular Weight Heparin versus Acenocoumarol in the Secondary Prophylaxis of Deep Vein ThrombosisThrombosis and Haemostasis, 81
T. Hyers, R. Hull, J. Weg (1992)
Antithrombotic therapy for venous thromboembolic disease.Chest, 102 4 Suppl
E. Altschuler, H. Moosa, R. Selker, F. Vertosick (1990)
The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors.Neurosurgery, 27 1
H. Büller, M. Gent, A. Gallus, Jeffrey Ginsberg, M. Prins, R. Baildon (1997)
Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.The New England journal of medicine, 337 10
M. Gould, A. Dembitzer, R. Doyle, T. Hastie, A. Garber (1999)
Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous ThrombosisAnnals of Internal Medicine, 130
T. Warkentin, Mark Levine, J. Hirsh, P. Horsewood, R. Roberts, M. Gent, J. Kelton (1995)
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.The New England journal of medicine, 332 20
J. Hirsh, J. Dalen, D. Anderson, L. Poller, H. Bussey, J. Ansell, D. Deykin (2001)
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.Chest, 119 1 Suppl
(2000)
A dose - response study of the factor VIIa / tissue factor inhibitor rNAPc 2 in the prevention of postoperative venous thromboembolism in patients undergoing total knee arthroplasty ( abstract )
T. Wentzien, R. O'Reilly, P. Kearns (1998)
Prospective evaluation of anticoagulant reversal with oral vitamin K1 while continuing warfarin therapy unchanged.Chest, 114 6
A. Kereveur, Samama Mm (1995)
[New antithrombotic agents].Presse medicale, 24 38
H. Eriksson, U. Eriksson, L. Frison, P. Hansson, P. Held, M. Holmström, A. Hägg, T. Jonsson, L. Lapidus, B. Leijd, D. Stockelberg, U. Säfwenberg, A. Taghavi, M. Thorsén (1999)
Pharmacokinetics and Pharmacodynamics of Melagatran, a Novel Synthetic LMW Thrombin Inhibitor, in Patients with Acute DVTThrombosis and Haemostasis, 81
P. Prandoni (2006)
Low molecular weight heparinsReactions Weekly, 1132
M. Pini, S. Aiello, C. Manotti, C. Pattacini, R. Quintavalla, T. Poli, A. Tagliaferri, A. Dettori (1994)
Low Molecular Weight Heparin versus Warfarin in the Prevention of Recurrences after Deep Vein ThrombosisThrombosis and Haemostasis, 72
(1999)
Subcutaneous and oral direct thrombin inhibitors for prophylaxis of deep venous thrombosis and pulmonary embolism after total hip and knee replacement ( abstract )
M. Gitter, T. Jaeger, T. Petterson, B. Gersh, M. Silverstein (1995)
Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota.Mayo Clinic proceedings, 70 8
D. Schiff, L. Deangelis (1994)
Therapy of venous thromboembolism in patients with brain metastasesCancer, 73
W. So, H. Hugenholtz, M. Richard (1983)
Complications of anticoagulant therapy in patients with known central nervous system lesions.Canadian journal of surgery. Journal canadien de chirurgie, 26 2
C. Kearon, M. Gent, J. Hirsh, J. Weitz, M. Kovacs, D. Anderson, A. Turpie, D. Green, Jeffrey Ginsberg, P. Wells, B. Mackinnon, J. Julian (1999)
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.The New England journal of medicine, 340 12
S. Rebello, H. Blank, W. Rote, G. Vlasuk, B. Lucchesi (1997)
Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration.The Journal of pharmacology and experimental therapeutics, 283 1
M. Koopman, P. Prandoni, F. Piovella, P. Ockelford, D. Brandjes, J. Meer, A. Gallus, G. Simonneau, Colin Chesterman, M. Prins, P. Bossuyt, H. Haes, A. Belt, L. Sagnard, Pascal d'Azemar, H. Büller (1996)
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.The New England journal of medicine, 334 11
Kevin Schulman (1995)
Cost-effectiveness analyses.The New England journal of medicine, 332 2
M. Levine, G. Raskob, S. Landefeld, C. Kearon (1992)
Hemorrhagic complications of anticoagulant treatment.Chest, 114 5 Suppl
H. Décousus, A. Leizorovicz, F. Parent, Y. Page, B. Tardy, Philippe Girard, S. Laporte, R. Faivre, B. Charbonnier, F. Barral, Y. Huet, G. Simonneau (1998)
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.The New England journal of medicine, 338 7
J. Walenga, W. Jeske, Lucienne Bara, M. Samama, J. Fareed (1997)
Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.Thrombosis research, 86 1
M. Levine, M. Gent, J. Hirsh, J. Leclerc, D. Anderson, J. Weitz, Jeffrey Ginsberg, A. Turpie, C. Demers, M. Kovacs (1996)
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.The New England journal of medicine, 334 11
K. Norrby (1993)
Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically.Haemostasis, 23 Suppl 1
J. Heit, C. Colwell, C. Francis, Jeffrey Ginsberg, S. Berkowitz, J. Whipple, G. Peters (2001)
Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.Archives of internal medicine, 161 18
R. Bona, K. Sivjee, A. Hickey, D. Wallace, Selby Wajcs (1995)
The Efficacy and Safety of Oral Anticoagulation in Patients with CancerThrombosis and Haemostasis, 74
F. Veiga, A. Escribá, M. Maluenda, M. Rubio, I. Margalet, A. Lezana, J. Gallego, J. Ribera (2000)
Low Molecular Weight Heparin (Enoxaparin) Versus Oral Anticoagulant Therapy (Acenocoumarol) in the Long-Term Treatment of Deep Venous Thrombosis in the Elderly: a Randomized TrialThrombosis and Haemostasis, 84
F. Meer, F. Rosendaal, J. Vandenbroucke, Ernest Bnet (1993)
Bleeding complications in oral anticoagulant therapy. An analysis of risk factors.Archives of internal medicine, 153 13
J. Heit, M. Silverstein, D. Mohr, T. Petterson, L. Melton (1999)
Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study.Archives of internal medicine, 159 5
(2000)
Long-term low molecular weight heparin treatment versus oral anticoagulant therapy for proximal deep vein thrombosis (abstract). Blood 2000;96:449a
M. Crowther, J. Julian, Donna McCarty, J. Douketis, M. Kovacs, Lee Biagoni, T. Schnurr, J. McGinnis, M. Gent, J. Hirsh, J. Ginsberg (2000)
Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trialThe Lancet, 356
P. Hansson, J. Sörbo, H. Eriksson (2000)
Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors.Archives of internal medicine, 160 6
P. Prandoni, M. Carta, A. Cogo, A. Ruol, M. Vigo, D. Casara, A. Lensing, H. Büller, J. Cate (1992)
Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosisThe Lancet, 339
P. Prandoni, A. Lensing, A. Cogo, S. Cuppini, S. Villalta, M. Carta, A. Cattelan, P. Polistena, E. Bernardi, M. Prins (1996)
The Long-Term Clinical Course of Acute Deep Venous ThrombosisAnnals of Internal Medicine, 125
(2000)
The PENTHIFRA study: Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin: The prevention of venous thromboembolism (VTE) after hip fracture surgery
M. Levine, J. Hirsh, M. Gent, A. Turpie, M. Cruickshank, J. Weitz, D. Anderson, M. Johnson (1994)
A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.Archives of internal medicine, 154 1
A. Chan, R. Woodruff (1992)
Complications and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy.Australian and New Zealand journal of medicine, 22 2
G. Palareti, C. Legnani, Agnes Lee, C. Manotti, J. Hirsh, A. D’Angelo, V. Pengo, M. Moia, S. Coccheri (2000)
A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without MalignancyThrombosis and Haemostasis, 84
Venous thromboembolism is a common complication in patients with cancer. The management of deep vein thrombosis and pulmonary embolism can be a considerable challenge in patients with cancer. The cancer itself and associated treatments contribute to an ongoing thrombogenic stimulus, while cancer patients are thought to be at increased risk for anticoagulant-induced bleeding. Initial treatment of acute thromboembolism is with intravenous unfractionated heparin or subcutaneous low molecular weight heparin. Treatment at home with low molecular weight heparin is an attractive option in patients with malignant disease. Long-term treatment of acute venous thromboembolism has traditionally been with oral anticoagulants. However, the inconvenience and narrow therapeutic window of oral anticoagulants make such therapy unattractive and problematic in cancer patients. Low molecular weight heparins are being evaluated as an alternative for long-term therapy because their anticoagulant effects are more predictable and laboratory monitoring is unnecessary. Although many clinical issues remain unresolved in the treatment of cancer patients with venous thromboembolism, the future holds much promise as new antithrombotic agents, including factor Xa antagonists and oral thrombin inhibitors, are being tested in clinical trials.
Acta Haematologica – Karger
Published: Sep 1, 2001
Keywords: Cancer; Thromboembolism, venous; Therapy
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.